Holen Sie sich die Stockscreener-App
121.05
1.04%
1.25
Handel nachbörslich:
121.04
-0.010
-0.01%
Kymera Therapeutics Inc Aktie (KYMR) Neueste Nachrichten
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Piper Sandler Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $140 - Moomoo
B of A, Truist raise Kymera Therapeutics price targets - scanx.trade
Eagle Health Investments LP Buys Shares of 166,148 Kymera Therapeutics, Inc. $KYMR - MarketBeat
Merck & Co. Inc. Takes Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
TimesSquare Capital Management LLC Purchases Shares of 157,327 Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics, Inc. $KYMR Shares Sold by Bank of America Corp DE - MarketBeat
Kymera Therapeutics (KYMR) Advances 3.42% to $121.41 as Protein Degradation Platform Gains Investor AttentionAnalyst Upgrade Stocks - vinanet.vn
Kymera Therapeutics Inc (KYMR) (Q2 2026) Earnings Call Highlight - GuruFocus
Kymera Therapeutics Stock Rockets 17% With 9-Day Winning Streak - Trefis
A 9-Day Winning Streak Has Kymera Therapeutics Stock Up 17% - Trefis
State of Wyoming Purchases New Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics (KYMR) Edges Higher by 1.4% as Shares Test Key Resistance at $121.87IV Spike - Vinanet
T. Rowe Price Associates (KYMR) reports 8.6% stake in Kymera Therapeutics - Stock Titan
Kymera Therapeutics Stock 8-Day Winning Spree: Stock Climbs 14% - Trefis
A 8-Day Winning Streak Has Kymera Therapeutics Stock Up 14% - Trefis
Atlas Venture funds (KYMR) report 3.4% beneficial stake in Kymera Therapeutics - Stock Titan
Stifel Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $132 - Moomoo
Kymera Therapeutics (KYMR) Q2 2026 Earnings Call Transcript - The Globe and Mail
Analysts’ Top Healthcare Picks: Metagenomi, Inc. (MGX), Kymera Therapeutics (KYMR) - The Globe and Mail
Kymera Therapeutics (NASDAQ:KYMR) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
(KYMR) Volatility Zones as Tactical Triggers - Stock Traders Daily
HC Wainwright Issues Negative Outlook for KYMR Earnings - MarketBeat
BofA Securities Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Cuts Target Price to $123 - Moomoo
California State Teachers Retirement System Increases Stake in Kymera Therapeutics, Inc. $KYMR - MarketBeat
J.P. Morgan Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $121 - Moomoo
Why Kymera Therapeutics (NASDAQ:KYMR) Is Drawing Fresh Attention This Week? - Kalkine Media
A Quick Look at Today's Ratings for Kymera Therapeutics(KYMR.US), With a Forecast Between $116 to $139 - Moomoo
Q3 EPS Forecast for Kymera Therapeutics Cut by Analyst - MarketBeat
RBC Capital Downgrades Kymera Therapeutics(KYMR.US) to Hold Rating, Raises Target Price to $112 - moomoo.com
KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments - finance.yahoo.com
KYMR Maintains Overweight by Barclays -- Price Target Raised to $139 - GuruFocus
KYMERA THERAPEUTICS, INC. : CITIGROUP RAISES TARGET PRICE TO $135 FROM $120 - Bitget
Kymera Therapeutics (KYMR) Stock Faces A Revenue Durability Reckoning - simplywall.st
Accelerated KT-621 Trial and Narrower Loss Might Change The Case For Investing In Kymera Therapeutics (KYMR) - finance.yahoo.com
KYMR SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
KYMR Looks 328.3% Overvalued on GF Value™ - GuruFocus
Kymera Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Kymera Therapeutics, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:KYMR) 2026-08-05 - Seeking Alpha
Kymera Therapeutics, Inc. Stock 12‑Month Price Target Raised to $128.91, Implies 23% Upside - TradingView
Kymera Therapeutics (NASDAQ:KYMR) Releases Earnings Results, Beats Estimates By $0.09 EPS - MarketBeat
Kymera Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Kymera Therapeutics Q2 Earnings Call Highlights - MarketBeat
Is Kymera Therapeutics Inc (KYMR) Overvalued After Q2 Earnings B - GuruFocus
Earnings call transcript: Kymera beats Q2 2026 estimates on revenue surge - Investing.com
Kymera Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Kymera Therapeutics Q2 Net Loss Narrows, Collaboration Revenue Rises - marketscreener.com
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings Flash (KYMR) Kymera Therapeutics Posts Q2 Loss $0.62 a Share, vs. FactSet Est of $0.71 Loss - marketscreener.com
Earnings Flash (KYMR) Kymera Therapeutics, Inc. Reports Q2 Collaboration Revenue $65.0M, vs. FactSet Est of $32.8M - marketscreener.com
Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update - The Manila Times
Milestones boost Kymera Therapeutics (NASDAQ: KYMR) Q2 2026 collaboration revenue - Stock Titan
Kymera Therapeutics Q2 collaboration revenue more than doubles, beats estimates - TradingView
Kymera Therapeutics posts Q2 loss, $1.5B cash runway; collaboration revenue $65M - TradingView
BRIEF-Kymera Therapeutics Q2 EPS USD -0.62 - TradingView
Press Release: Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update - Moomoo
Kymera Therapeutics posts corporate deck outlining push to develop oral targeted protein degraders for immunology - Bitget
Kymera earnings up next: Can degrader platform justify rally? - Investing.com
Kymera earnings up next: Can degrader platform justify rally? By Investing.com - Investing.com Nigeria
The Manufacturers Life Insurance Company Cuts Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Earnings To Watch: Kymera Therapeutics Inc (KYMR) Q2 2026 -- GF Value Sees 80% Downside - GuruFocus
Kymera Therapeutics, Inc. (KYMR) Stock Analysis: Exploring a Potential 26.79% Upside in the Biotech Frontier - DirectorsTalk Interviews
Kymera Therapeutics, Inc. $KYMR Stock Holdings Trimmed by Dimensional Fund Advisors LP - MarketBeat
First Trust Advisors LP Boosts Stock Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics (KYMR) Projected to Announce Quarterly Earnings on Wednesday - MarketBeat
Deutsche Bank Initiates Kymera Therapeutics at Hold, With $120 Price Target - marketscreener.com
Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026 - The Manila Times
0.00%
3.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):